<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35536431</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1863-2300</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>Seminars in immunopathology</Title>
          <ISOAbbreviation>Semin Immunopathol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The intestinal and biliary microbiome in autoimmune liver disease-current evidence and concepts.</ArticleTitle>
        <Pagination>
          <StartPage>1</StartPage>
          <EndPage>23</EndPage>
          <MedlinePgn>1-23</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00281-022-00936-6</ELocationID>
        <Abstract>
          <AbstractText>Autoimmune liver diseases are a group of immune-mediated liver diseases with three distinct entities, including autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis. The interplay of genetic and environmental factors leads to the breakdown of self-tolerance, resulting in hyper-responsiveness, and auto-aggressive immune activation. Emerging evidence links autoimmune liver diseases with alterations of the commensal microbiome configuration and aberrant immune system activation by microbial signals, mainly via the gut-liver axis. Thus, the microbiome is a new frontier to deepen the pathogenetic understanding, uncover biomarkers, and inspire innovative treatments. Herein, we review the current evidence on the role of the microbiome in autoimmune liver diseases from both clinical and basic research. We highlight recent achievements and also bottlenecks and limitations. Moreover, we give an outlook on future developments and potential for clinical applications.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Liwinski</LastName>
            <ForeName>Timur</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-1041-9142</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany. liwinskt@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Heinemann</LastName>
            <ForeName>Melina</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schramm</LastName>
            <ForeName>Christoph</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Martin Zeitz Center for Rare Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Semin Immunopathol</MedlineTA>
        <NlmUniqueID>101308769</NlmUniqueID>
        <ISSNLinking>1863-2297</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Autoimmune hepatitis</Keyword>
        <Keyword MajorTopicYN="N">Autoimmunity</Keyword>
        <Keyword MajorTopicYN="N">Intestinal barrier</Keyword>
        <Keyword MajorTopicYN="N">Liver disease</Keyword>
        <Keyword MajorTopicYN="N">Microbiome</Keyword>
        <Keyword MajorTopicYN="N">Microbiota</Keyword>
        <Keyword MajorTopicYN="N">Primary biliary cholangitis</Keyword>
        <Keyword MajorTopicYN="N">Primary sclerosing cholangitis</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>11</Hour>
          <Minute>18</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35536431</ArticleId>
        <ArticleId IdType="pmc">PMC9088151</ArticleId>
        <ArticleId IdType="doi">10.1007/s00281-022-00936-6</ArticleId>
        <ArticleId IdType="pii">10.1007/s00281-022-00936-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Engel B, Taubert R, Jaeckel E, Manns MP. The future of autoimmune liver diseases - understanding pathogenesis and improving morbidity and mortality. Liver Int. 2020;40(Suppl 1):149–153. doi: 10.1111/liv.14378.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/liv.14378</ArticleId>
            <ArticleId IdType="pubmed">32077605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hennes EM, Zeniya M, Czaja AJ, et al.  Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–76. doi: 10.1002/hep.22322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.22322</ArticleId>
            <ArticleId IdType="pubmed">18537184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lleo A, Wang G-Q, Gershwin ME, Hirschfield GM (2020) Primary biliary cholangitis. Lancet (London, England) 39610.1016/S0140-6736(20)31607-X</Citation>
        </Reference>
        <Reference>
          <Citation>Dyson JK, Beuers U, Jones DEJ, et al (2018) Primary sclerosing cholangitis. Lancet (London, England) 39110.1016/S0140-6736(18)30300-3</Citation>
        </Reference>
        <Reference>
          <Citation>Lammert C (2019) Genetic and environmental risk factors for autoimmune hepatitis. Clin liver Dis 1410.1002/cld.798</Citation>
        </Reference>
        <Reference>
          <Citation>Qiu F, Tang R, Zuo X, et al (2017) A genome-wide association study identifies six novel risk loci for primary biliary cholangitis. Nat Commun 810.1038/ncomms14828</Citation>
        </Reference>
        <Reference>
          <Citation>Alberts R, de Vries EMG, Goode EC, et al.  Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut. 2018;67:1517–1524. doi: 10.1136/gutjnl-2016-313598.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2016-313598</ArticleId>
            <ArticleId IdType="pmc">PMC5797498</ArticleId>
            <ArticleId IdType="pubmed">28779025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitchell SA, Thyssen M, Orchard TR, et al.  Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study. Gut. 2002;51:567–73. doi: 10.1136/gut.51.4.567.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.51.4.567</ArticleId>
            <ArticleId IdType="pmc">PMC1773401</ArticleId>
            <ArticleId IdType="pubmed">12235082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dyson JK, Webb G, Hirschfield GM, et al.  Unmet clinical need in autoimmune liver diseases. J Hepatol. 2015;62:208–18. doi: 10.1016/j.jhep.2014.09.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2014.09.010</ArticleId>
            <ArticleId IdType="pubmed">25234946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carbone M, Neuberger JM. Autoimmune liver disease, autoimmunity and liver transplantation. J Hepatol. 2014;60:210–23. doi: 10.1016/j.jhep.2013.09.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2013.09.020</ArticleId>
            <ArticleId IdType="pubmed">24084655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeuzem S (2000) Gut-liver axis. Int J Colorectal Dis 1510.1007/s003840050236</Citation>
        </Reference>
        <Reference>
          <Citation>Gilbert JA, Blaser MJ, Caporaso JG, et al.  Current understanding of the human microbiome. Nat Med. 2018;24:392–400. doi: 10.1038/nm.4517.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.4517</ArticleId>
            <ArticleId IdType="pmc">PMC7043356</ArticleId>
            <ArticleId IdType="pubmed">29634682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liwinski T, Leshem A, Elinav E. Breakthroughs and bottlenecks in microbiome research. Trends Mol Med. 2021;27:298–301. doi: 10.1016/j.molmed.2021.01.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molmed.2021.01.003</ArticleId>
            <ArticleId IdType="pubmed">33563544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tripathi A, Debelius J, Brenner DA, et al.  The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15:397–411. doi: 10.1038/s41575-018-0011-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41575-018-0011-z</ArticleId>
            <ArticleId IdType="pmc">PMC6319369</ArticleId>
            <ArticleId IdType="pubmed">29748586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiest R, Albillos A, Trauner M, et al.  Targeting the gut-liver axis in liver disease. J Hepatol. 2017;67:1084–1103. doi: 10.1016/j.jhep.2017.05.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2017.05.007</ArticleId>
            <ArticleId IdType="pubmed">28526488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manns MP, Lohse AW, Vergani D. Autoimmune hepatitis–update 2015. J Hepatol. 2015;62:S100–11. doi: 10.1016/j.jhep.2015.03.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2015.03.005</ArticleId>
            <ArticleId IdType="pubmed">25920079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mack CL, Adams D, Assis DN, et al.  Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020;72:671–722. doi: 10.1002/hep.31065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.31065</ArticleId>
            <ArticleId IdType="pubmed">31863477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>European Association for the Study of the Liver  EASL Clinical Practice Guidelines: autoimmune hepatitis. J Hepatol. 2015;63:971–1004. doi: 10.1016/j.jhep.2015.06.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2015.06.030</ArticleId>
            <ArticleId IdType="pubmed">26341719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindor KD, Bowlus CL, Boyer J, et al.  Primary biliary cholangitis: 2018 practice guidance from the american association for the study of liver diseases. Hepatology. 2019;69:394–419. doi: 10.1002/hep.30145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.30145</ArticleId>
            <ArticleId IdType="pubmed">30070375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>European Association for the Study of the Liver  EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237–267. doi: 10.1016/j.jhep.2009.04.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2009.04.009</ArticleId>
            <ArticleId IdType="pubmed">19501929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirschfield GM, Beuers U, Corpechot C, et al.  EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67:145–172. doi: 10.1016/j.jhep.2017.03.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2017.03.022</ArticleId>
            <ArticleId IdType="pubmed">28427765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Vries E, Bolier R, Goet J, et al.  Fibrates for Itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial. Gastroenterology. 2021;160:734–743.e6. doi: 10.1053/j.gastro.2020.10.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2020.10.001</ArticleId>
            <ArticleId IdType="pubmed">33031833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aabakken L, Karlsen TH, Albert J, et al.  Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. Endoscopy. 2017;49:588–608. doi: 10.1055/s-0043-107029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0043-107029</ArticleId>
            <ArticleId IdType="pubmed">28420030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sender R, Fuchs S, Milo R. Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell. 2016;164:337–340. doi: 10.1016/j.cell.2016.01.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2016.01.013</ArticleId>
            <ArticleId IdType="pubmed">26824647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morgan XC, Huttenhower C. Chapter 12 Human microbiome analysis. PLoS Comput Biol. 2012;8:e1002808. doi: 10.1371/journal.pcbi.1002808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pcbi.1002808</ArticleId>
            <ArticleId IdType="pmc">PMC3531975</ArticleId>
            <ArticleId IdType="pubmed">23300406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dethlefsen L, McFall-Ngai M, Relman DA (2007) An ecological and evolutionary perspective on human-microbe mutualism and disease. Nature 44910.1038/nature06245</Citation>
        </Reference>
        <Reference>
          <Citation>Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30:492–506. doi: 10.1038/s41422-020-0332-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41422-020-0332-7</ArticleId>
            <ArticleId IdType="pmc">PMC7264227</ArticleId>
            <ArticleId IdType="pubmed">32433595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gensollen T, Iyer SS, Kasper DL, Blumberg RS. How colonization by microbiota in early life shapes the immune system. Science. 2016;352:539–544. doi: 10.1126/science.aad9378.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aad9378</ArticleId>
            <ArticleId IdType="pmc">PMC5050524</ArticleId>
            <ArticleId IdType="pubmed">27126036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Russell SL, Gold MJ, Hartmann M, et al.  Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. EMBO Rep. 2012;13:440–7. doi: 10.1038/embor.2012.32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/embor.2012.32</ArticleId>
            <ArticleId IdType="pmc">PMC3343350</ArticleId>
            <ArticleId IdType="pubmed">22422004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korpela K, Helve O, Kolho KL, et al.  Maternal fecal microbiota transplantation in cesarean-born infants rapidly restores normal gut microbial development: a proof-of-concept study. Cell. 2020;183:324–334.e5. doi: 10.1016/j.cell.2020.08.047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.08.047</ArticleId>
            <ArticleId IdType="pubmed">33007265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arpaia N, Campbell C, Fan X, et al.  Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504:451–455. doi: 10.1038/nature12726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature12726</ArticleId>
            <ArticleId IdType="pmc">PMC3869884</ArticleId>
            <ArticleId IdType="pubmed">24226773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miossec P, Kolls JK. Targeting IL-17 and T H 17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11:763–776. doi: 10.1038/nrd3794.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd3794</ArticleId>
            <ArticleId IdType="pubmed">23023676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Omenetti S, Bussi C, Metidji A, et al.  The intestine harbors functionally distinct homeostatic tissue-resident and inflammatory Th17 cells. Immunity. 2019;51:77–89.e6. doi: 10.1016/j.immuni.2019.05.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2019.05.004</ArticleId>
            <ArticleId IdType="pmc">PMC6642154</ArticleId>
            <ArticleId IdType="pubmed">31229354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bachem A, Makhlouf C, Binger KJ, de Souza DP, Tull D, Hochheiser K, Whitney PG. Microbiota-derived short-chain fatty acids promote the memory potential of antigen-activated CD8 + T cells. Immunity. 2019;51:285–297. doi: 10.1016/j.immuni.2019.06.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2019.06.002</ArticleId>
            <ArticleId IdType="pubmed">31272808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ridlon JM, Kang D-J, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2006;47:241–59. doi: 10.1194/jlr.R500013-JLR200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1194/jlr.R500013-JLR200</ArticleId>
            <ArticleId IdType="pubmed">16299351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song X, Sun X, Oh SF, et al (2020) Microbial bile acid metabolites modulate gut RORγ+ regulatory T cell homeostasis. Nature 57710.1038/s41586-019-1865-0</Citation>
        </Reference>
        <Reference>
          <Citation>Hang S, Paik D, Yao L, et al.  Bile acid metabolites control TH17 and Treg cell differentiation. Nature. 2019;576:143–148. doi: 10.1038/s41586-019-1785-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1785-z</ArticleId>
            <ArticleId IdType="pmc">PMC6949019</ArticleId>
            <ArticleId IdType="pubmed">31776512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato Y, Atarashi K, Plichta DR, et al.  Novel bile acid biosynthetic pathways are enriched in the microbiome of centenarians. Nature. 2021 doi: 10.1038/s41586-021-03832-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-03832-5</ArticleId>
            <ArticleId IdType="pmc">PMC8828475</ArticleId>
            <ArticleId IdType="pubmed">34823256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chopyk DM, Grakoui A. Contribution of the intestinal microbiome and gut barrier to hepatic disorders. Gastroenterology. 2020;159:849–863. doi: 10.1053/j.gastro.2020.04.077.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2020.04.077</ArticleId>
            <ArticleId IdType="pmc">PMC7502510</ArticleId>
            <ArticleId IdType="pubmed">32569766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farquhar M, Palade G. Junctional complexes in various epithelia. J Cell Biol. 1963;17:375–412. doi: 10.1083/jcb.17.2.375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.17.2.375</ArticleId>
            <ArticleId IdType="pmc">PMC2106201</ArticleId>
            <ArticleId IdType="pubmed">13944428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiippala K, Jouhten H, Ronkainen A, et al.  The potential of gut commensals in reinforcing intestinal barrier function and alleviating inflammation. Nutrients. 2018;10:988. doi: 10.3390/nu10080988.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/nu10080988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cornick S, Tawiah A, Chadee K. Roles and regulation of the mucus barrier in the gut. Tissue barriers. 2015;3:e982426. doi: 10.4161/21688370.2014.982426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/21688370.2014.982426</ArticleId>
            <ArticleId IdType="pmc">PMC4372027</ArticleId>
            <ArticleId IdType="pubmed">25838985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng L, Li Z-R, Green RS, et al.  Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr. 2009;139:1619–25. doi: 10.3945/jn.109.104638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3945/jn.109.104638</ArticleId>
            <ArticleId IdType="pmc">PMC2728689</ArticleId>
            <ArticleId IdType="pubmed">19625695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wexler HM. Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev. 2007;20:593–621. doi: 10.1128/CMR.00008-07.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/CMR.00008-07</ArticleId>
            <ArticleId IdType="pmc">PMC2176045</ArticleId>
            <ArticleId IdType="pubmed">17934076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Csak T, Ganz M, Pespisa J, et al.  Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology. 2011;54:133–44. doi: 10.1002/hep.24341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.24341</ArticleId>
            <ArticleId IdType="pmc">PMC4158408</ArticleId>
            <ArticleId IdType="pubmed">21488066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uesugi T, Froh M, Arteel GE, et al.  Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology. 2001;34:101–8. doi: 10.1053/jhep.2001.25350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/jhep.2001.25350</ArticleId>
            <ArticleId IdType="pubmed">11431739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seki E, De Minicis S, Osterreicher CH, et al.  TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med. 2007;13:1324–32. doi: 10.1038/nm1663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm1663</ArticleId>
            <ArticleId IdType="pubmed">17952090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wells JM, Brummer RJ, Derrien M, et al (2017) Homeostasis of the gut barrier and potential biomarkers. Am J Physiol Gastrointest Liver Physiol 31210.1152/ajpgi.00048.2015</Citation>
        </Reference>
        <Reference>
          <Citation>Kim D-H, Sim Y, Hwang J-H, et al.  Ellagic acid prevents binge alcohol-induced leaky gut and liver injury through inhibiting gut dysbiosis and oxidative stress. Antioxidants (Basel, Switzerland) 2021;10:1386. doi: 10.3390/antiox10091386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/antiox10091386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kinashi Y, Hase K. Partners in leaky gut syndrome: intestinal dysbiosis and autoimmunity. Front Immunol. 2021;12:673708. doi: 10.3389/fimmu.2021.673708.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2021.673708</ArticleId>
            <ArticleId IdType="pmc">PMC8100306</ArticleId>
            <ArticleId IdType="pubmed">33968085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grosheva I, Zheng D, Levy M, et al.  High-throughput screen identifies host and microbiota regulators of intestinal barrier function. Gastroenterology. 2020;159:1807–1823. doi: 10.1053/j.gastro.2020.07.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2020.07.003</ArticleId>
            <ArticleId IdType="pubmed">32653496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ercolini AM, Miller SD. The role of infections in autoimmune disease. Clin Exp Immunol. 2009;155:1–15. doi: 10.1111/j.1365-2249.2008.03834.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2249.2008.03834.x</ArticleId>
            <ArticleId IdType="pmc">PMC2665673</ArticleId>
            <ArticleId IdType="pubmed">19076824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vangay P, Ward T, Gerber JS, Knights D. Antibiotics, pediatric dysbiosis, and disease. Cell Host Microbe. 2015;17:553–564. doi: 10.1016/j.chom.2015.04.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2015.04.006</ArticleId>
            <ArticleId IdType="pmc">PMC5555213</ArticleId>
            <ArticleId IdType="pubmed">25974298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai W, Ran Y, Li Y, et al.  Intestinal microbiome and permeability in patients with autoimmune hepatitis. Best Pract Res Clin Gastroenterol. 2017;31:669–673. doi: 10.1016/j.bpg.2017.09.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bpg.2017.09.013</ArticleId>
            <ArticleId IdType="pubmed">29566910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ngu JH, Gearry RB, Frampton CM, Stedman CAM. Autoimmune hepatitis: the role of environmental risk factors: a population-based study. Hepatol Int. 2013;7:869–875. doi: 10.1007/s12072-013-9448-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12072-013-9448-x</ArticleId>
            <ArticleId IdType="pubmed">26201924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paiardini A, Pascarella S. Structural mimicry between SLA/LP and Rickettsia surface antigens as a driver of autoimmune hepatitis: insights from an in silico study. Theor Biol Med Model. 2013;10:25. doi: 10.1186/1742-4682-10-25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1742-4682-10-25</ArticleId>
            <ArticleId IdType="pmc">PMC3636016</ArticleId>
            <ArticleId IdType="pubmed">23575112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Floreani A, Restrepo-Jiménez P, Secchi MF, et al.  Etiopathogenesis of autoimmune hepatitis. J Autoimmun. 2018;95:133–143. doi: 10.1016/j.jaut.2018.10.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2018.10.020</ArticleId>
            <ArticleId IdType="pubmed">30385083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis. Lancet (London, England) 2011;377:1600–1609. doi: 10.1016/S0140-6736(10)61965-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(10)61965-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka A, Leung PSC, Gershwin ME. Pathogen infections and primary biliary cholangitis. Clin Exp Immunol. 2019;195:25–34. doi: 10.1111/cei.13198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cei.13198</ArticleId>
            <ArticleId IdType="pmc">PMC6300644</ArticleId>
            <ArticleId IdType="pubmed">30099750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bogdanos DP, Vergani D. Bacteria and primary biliary cirrhosis. Clin Rev Allergy Immunol. 2009;36:30–39. doi: 10.1007/s12016-008-8087-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12016-008-8087-9</ArticleId>
            <ArticleId IdType="pubmed">18498061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Selmi C, Balkwill DL, Invernizzi P, et al.  Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology. 2003;38:1250–1257. doi: 10.1053/jhep.2003.50446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/jhep.2003.50446</ArticleId>
            <ArticleId IdType="pubmed">14578864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen W, Wei Y, Xiong A, et al.  Comprehensive analysis of serum and fecal bile acid profiles and interaction with gut microbiota in primary biliary cholangitis. Clin Rev Allergy Immunol. 2020;58:25–38. doi: 10.1007/s12016-019-08731-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12016-019-08731-2</ArticleId>
            <ArticleId IdType="pubmed">30900136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katt J, Schwinge D, Schoknecht T, et al.  Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis. Hepatology. 2013;58:1084–1093. doi: 10.1002/hep.26447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.26447</ArticleId>
            <ArticleId IdType="pubmed">23564624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rupp C, Bode KA, Chahoud F, et al.  Risk factors and outcome in patients with primary sclerosing cholangitis with persistent biliary candidiasis. BMC Infect Dis. 2014;14:562. doi: 10.1186/s12879-014-0562-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12879-014-0562-8</ArticleId>
            <ArticleId IdType="pmc">PMC4209225</ArticleId>
            <ArticleId IdType="pubmed">25338733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tabibian JH, Weeding E, Jorgensen RA, et al.  Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther. 2013;37:604–612. doi: 10.1111/apt.12232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/apt.12232</ArticleId>
            <ArticleId IdType="pubmed">23384404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Färkkilä M, Karvonen A-L, Nurmi H, et al.  Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology. 2004;40:1379–1386. doi: 10.1002/hep.20457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.20457</ArticleId>
            <ArticleId IdType="pubmed">15565569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silveira MG, Torok NJ, Gossard AA, et al.  Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol. 2009;104:83–88. doi: 10.1038/ajg.2008.14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ajg.2008.14</ArticleId>
            <ArticleId IdType="pubmed">19098854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davies YK, Cox KM, Abdullah BA, et al.  Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr. 2008;47:61–67. doi: 10.1097/MPG.0b013e31816fee95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MPG.0b013e31816fee95</ArticleId>
            <ArticleId IdType="pubmed">18607270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah A, Crawford D, Burger D, et al.  Effects of antibiotic therapy in primary sclerosing cholangitis with and without inflammatory bowel disease: a systematic review and meta-analysis. Semin Liver Dis. 2019;39:432–441. doi: 10.1055/s-0039-1688501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0039-1688501</ArticleId>
            <ArticleId IdType="pubmed">31315136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Thiel DH, Carroll P, Abu-Elmagd K, et al.  Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol. 1995;90:455–459.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2982698</ArticleId>
            <ArticleId IdType="pubmed">7532912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan L-Z, Reilly CR, Steward-Harrison LC, et al.  Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis-ulcerative colitis. Gut. 2019;68:1533–1535. doi: 10.1136/gutjnl-2018-316599.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2018-316599</ArticleId>
            <ArticleId IdType="pubmed">30131321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deneau MR, Mack C, Mogul D, et al.  Oral vancomycin, ursodeoxycholic acid, or no therapy for pediatric primary sclerosing cholangitis: a matched analysis. Hepatology. 2021;73:1061–1073. doi: 10.1002/hep.31560.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.31560</ArticleId>
            <ArticleId IdType="pmc">PMC8557636</ArticleId>
            <ArticleId IdType="pubmed">32946600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terjung B, Söhne J, Lechtenberg B, et al.  p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut. 2010;59:808–816. doi: 10.1136/gut.2008.157818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.2008.157818</ArticleId>
            <ArticleId IdType="pubmed">19951907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kunzmann LK, Schoknecht T, Poch T, et al.  Monocytes as potential mediators of pathogen-induced T-Helper 17 differentiation in patients with primary sclerosing cholangitis (PSC) Hepatology. 2020;72:1310–1326. doi: 10.1002/hep.31140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.31140</ArticleId>
            <ArticleId IdType="pubmed">33090557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trivedi PJ, Tickle J, Vesterhus MN, et al.  Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner. Gut. 2018;67:1135–1145. doi: 10.1136/gutjnl-2016-312354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2016-312354</ArticleId>
            <ArticleId IdType="pmc">PMC5969351</ArticleId>
            <ArticleId IdType="pubmed">28428344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Derer S, Brethack A-K, Pietsch C, et al.  Inflammatory bowel disease-associated GP2 autoantibodies inhibit mucosal immune response to adherent-invasive bacteria. Inflamm Bowel Dis. 2020;26:1856–1868. doi: 10.1093/ibd/izaa069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ibd/izaa069</ArticleId>
            <ArticleId IdType="pubmed">32304568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jendrek ST, Gotthardt D, Nitzsche T, et al.  Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Gut. 2017;66:137–144. doi: 10.1136/gutjnl-2016-311739.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2016-311739</ArticleId>
            <ArticleId IdType="pubmed">27406039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allegretti JR, Kassam Z, Carrellas M, et al.  Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial. Am J Gastroenterol. 2019;114:1071–1079. doi: 10.14309/ajg.0000000000000115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14309/ajg.0000000000000115</ArticleId>
            <ArticleId IdType="pubmed">30730351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver. 2001;21:225–232. doi: 10.1034/j.1600-0676.2001.021004225.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1034/j.1600-0676.2001.021004225.x</ArticleId>
            <ArticleId IdType="pubmed">11454184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marceau G, Lapierre P, Béland K, et al.  LKM1 autoantibodies in chronic hepatitis C infection: a case of molecular mimicry? Hepatology. 2005;42:675–682. doi: 10.1002/hep.20816.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.20816</ArticleId>
            <ArticleId IdType="pubmed">16037945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liberal R, Krawitt EL, Vierling JM, et al.  Cutting edge issues in autoimmune hepatitis. J Autoimmun. 2016;75:6–19. doi: 10.1016/j.jaut.2016.07.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2016.07.005</ArticleId>
            <ArticleId IdType="pubmed">27502148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu L, Shen Z, Guo L, et al.  Does a betaretrovirus infection trigger primary biliary cirrhosis? Proc Natl Acad Sci U S A. 2003;100:8454–8459. doi: 10.1073/pnas.1433063100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1433063100</ArticleId>
            <ArticleId IdType="pmc">PMC166250</ArticleId>
            <ArticleId IdType="pubmed">12832623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Selmi C, Ross SR, Ansari AA, et al.  Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. Gastroenterology. 2004;127:493–501. doi: 10.1053/j.gastro.2004.05.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2004.05.033</ArticleId>
            <ArticleId IdType="pubmed">15300582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johal H, Scott GM, Jones R, et al.  Mouse mammary tumour virus-like virus (MMTV-LV) is present within the liver in a wide range of hepatic disorders and unrelated to nuclear p53 expression or hepatocarcinogenesis. J Hepatol. 2009;50:548–554. doi: 10.1016/j.jhep.2008.10.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2008.10.026</ArticleId>
            <ArticleId IdType="pubmed">19168254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SR, Imoto S, Taniguchi M, et al.  Primary sclerosing cholangitis and hepatitis C virus infection. Intervirology. 2005;48:268–272. doi: 10.1159/000084605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000084605</ArticleId>
            <ArticleId IdType="pubmed">15920352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nayudu SK, Kumbum K, Balar B, et al.  Small duct primary sclerosing cholangitis in association with hepatitis c virus infection: a case report. Gastroenterol Res. 2011;4:39–41. doi: 10.4021/gr282w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4021/gr282w</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takegoshi K, Nakanuma Y, Tsukada K, Okuda K. Human T-lymphotropic virus type 1-associated myelopathy and primary sclerosing cholangitis. J Clin Gastroenterol. 1991;13:202–204. doi: 10.1097/00004836-199104000-00017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00004836-199104000-00017</ArticleId>
            <ArticleId IdType="pubmed">2033229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vuille-Lessard É, Montani M, Bosch J, Semmo N. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination. J Autoimmun. 2021;123:102710. doi: 10.1016/j.jaut.2021.102710.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2021.102710</ArticleId>
            <ArticleId IdType="pmc">PMC8316013</ArticleId>
            <ArticleId IdType="pubmed">34332438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McShane C, Kiat C, Rigby J, Crosbie Ó. The mRNA COVID-19 vaccine - a rare trigger of autoimmune hepatitis? J Hepatol. 2021;75:1252–1254. doi: 10.1016/j.jhep.2021.06.044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2021.06.044</ArticleId>
            <ArticleId IdType="pmc">PMC8264276</ArticleId>
            <ArticleId IdType="pubmed">34245804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh B, Kaur P, Maroules M. Autoimmune hepatitis-primary biliary cholangitis overlap syndrome triggered by COVID-19. Eur J case reports Intern Med. 2021;8:002264. doi: 10.12890/2021_002264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12890/2021_002264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knight R, Vrbanac A, Taylor BC, et al.  Best practices for analysing microbiomes. Nat Rev Microbiol. 2018;16:410–422. doi: 10.1038/s41579-018-0029-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41579-018-0029-9</ArticleId>
            <ArticleId IdType="pubmed">29795328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lou J, Jiang Y, Rao B, et al.  Fecal microbiomes distinguish patients with autoimmune hepatitis from healthy individuals. Front Cell Infect Microbiol. 2020;10:342. doi: 10.3389/fcimb.2020.00342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcimb.2020.00342</ArticleId>
            <ArticleId IdType="pmc">PMC7416601</ArticleId>
            <ArticleId IdType="pubmed">32850468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elsherbiny NM, Rammadan M, Hassan EA, et al.  Autoimmune hepatitis: shifts in gut microbiota and metabolic pathways among Egyptian patients. Microorganisms. 2020;8:1011. doi: 10.3390/microorganisms8071011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/microorganisms8071011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liwinski T, Casar C, Ruehlemann MC, et al (2020) A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis. Aliment Pharmacol Ther in press:</Citation>
        </Reference>
        <Reference>
          <Citation>Wei Y, Li Y, Yan L, et al.  Alterations of gut microbiome in autoimmune hepatitis. Gut. 2019 doi: 10.1136/gutjnl-2018-317836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2018-317836</ArticleId>
            <ArticleId IdType="pubmed">31776228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin R, Zhou L, Zhang J, Wang B. Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis. Int J Clin Exp Pathol. 2015;8:5153–5160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4503083</ArticleId>
            <ArticleId IdType="pubmed">26191211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abe K, Takahashi A, Fujita M, et al.  Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease. PLoS ONE. 2018;13:e0198757. doi: 10.1371/journal.pone.0198757.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0198757</ArticleId>
            <ArticleId IdType="pmc">PMC6029758</ArticleId>
            <ArticleId IdType="pubmed">29969462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lv L-X, Fang D-Q, Shi D, et al.  Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis. Environ Microbiol. 2016;18:2272–2286. doi: 10.1111/1462-2920.13401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1462-2920.13401</ArticleId>
            <ArticleId IdType="pubmed">27243236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang R, Wei Y, Li Y, et al.  Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut. 2018;67:534–571. doi: 10.1136/gutjnl-2016-313332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2016-313332</ArticleId>
            <ArticleId IdType="pubmed">28213609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lammert C, Shin AS, Xu H, et al.  Short-chain fatty acid and fecal microbiota profiles are linked to fibrosis in primary biliary cholangitis. FEMS Microbiol Lett. 2021;368:fnab038. doi: 10.1093/femsle/fnab038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/femsle/fnab038</ArticleId>
            <ArticleId IdType="pmc">PMC8062329</ArticleId>
            <ArticleId IdType="pubmed">33836051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furukawa M, Moriya K, Nakayama J, et al.  Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis. Hepatol Res. 2020;50:840–852. doi: 10.1111/hepr.13509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/hepr.13509</ArticleId>
            <ArticleId IdType="pubmed">32346970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quraishi MN, Acharjee A, Beggs AD, et al.  A pilot integrative analysis of colonic gene expression, gut microbiota, and immune infiltration in primary sclerosing cholangitis-inflammatory bowel disease: association of disease with bile acid pathways. J Crohns Colitis. 2020;14:935–947. doi: 10.1093/ecco-jcc/jjaa021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjaa021</ArticleId>
            <ArticleId IdType="pmc">PMC7392170</ArticleId>
            <ArticleId IdType="pubmed">32016358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quraishi MN, Sergeant M, Kay G, et al.  The gut-adherent microbiota of PSC-IBD is distinct to that of IBD. Gut. 2017;66:386–388. doi: 10.1136/gutjnl-2016-311915.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2016-311915</ArticleId>
            <ArticleId IdType="pubmed">27196590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torres J, Bao X, Goel A, et al.  The features of mucosa-associated microbiota in primary sclerosing cholangitis. Aliment Pharmacol Ther. 2016;43:790–801. doi: 10.1111/apt.13552.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/apt.13552</ArticleId>
            <ArticleId IdType="pmc">PMC5177987</ArticleId>
            <ArticleId IdType="pubmed">26857969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kevans D, Tyler AD, Holm K, et al.  Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis. J Crohns Colitis. 2016;10:330–337. doi: 10.1093/ecco-jcc/jjv204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjv204</ArticleId>
            <ArticleId IdType="pmc">PMC4957469</ArticleId>
            <ArticleId IdType="pubmed">26526357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossen NG, Fuentes S, Boonstra K, et al.  The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II. J Crohns Colitis. 2015;9:342–348. doi: 10.1093/ecco-jcc/jju023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jju023</ArticleId>
            <ArticleId IdType="pubmed">25547975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rühlemann M, Liwinski T, Heinsen F-A, et al.  Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis. Aliment Pharmacol Ther. 2019;50:580–589. doi: 10.1111/apt.15375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/apt.15375</ArticleId>
            <ArticleId IdType="pmc">PMC6899739</ArticleId>
            <ArticleId IdType="pubmed">31250469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rühlemann MC, Heinsen F-A, Zenouzi R, et al.  Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis. Gut. 2017;66:753–754. doi: 10.1136/gutjnl-2016-312180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2016-312180</ArticleId>
            <ArticleId IdType="pubmed">27216937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kummen M, Holm K, Anmarkrud JA, et al.  The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut. 2017;66:611–619. doi: 10.1136/gutjnl-2015-310500.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2015-310500</ArticleId>
            <ArticleId IdType="pubmed">26887816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bajer L, Kverka M, Kostovcik M, et al.  Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis. World J Gastroenterol. 2017;23:4548–4558. doi: 10.3748/wjg.v23.i25.4548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v23.i25.4548</ArticleId>
            <ArticleId IdType="pmc">PMC5504370</ArticleId>
            <ArticleId IdType="pubmed">28740343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabino J, Vieira-Silva S, Machiels K, et al.  Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut. 2016;65:1681–1689. doi: 10.1136/gutjnl-2015-311004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2015-311004</ArticleId>
            <ArticleId IdType="pmc">PMC5036217</ArticleId>
            <ArticleId IdType="pubmed">27207975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lemoinne S, Kemgang A, Ben Belkacem K, et al.  Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. Gut. 2020;69:92–102. doi: 10.1136/gutjnl-2018-317791.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2018-317791</ArticleId>
            <ArticleId IdType="pubmed">31003979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Q, Li B, Li Y, et al.  Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis. Gut. 2021 doi: 10.1136/gutjnl-2020-323565.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2020-323565</ArticleId>
            <ArticleId IdType="pubmed">34937766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kummen M, Thingholm LB, Rühlemann MC, et al.  Altered gut microbial metabolism of essential nutrients in primary sclerosing cholangitis. Gastroenterology. 2021;160:1784–1798.e0. doi: 10.1053/j.gastro.2020.12.058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2020.12.058</ArticleId>
            <ArticleId IdType="pmc">PMC7611822</ArticleId>
            <ArticleId IdType="pubmed">33387530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iwasawa K, Suda W, Tsunoda T, et al.  Characterisation of the faecal microbiota in Japanese patients with paediatric-onset primary sclerosing cholangitis. Gut. 2017;66:1344–1346. doi: 10.1136/gutjnl-2016-312533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2016-312533</ArticleId>
            <ArticleId IdType="pmc">PMC5530472</ArticleId>
            <ArticleId IdType="pubmed">27670376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin N, Yang F, Li A, et al.  Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513:59–64. doi: 10.1038/nature13568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13568</ArticleId>
            <ArticleId IdType="pubmed">25079328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gevers D, Kugathasan S, Denson LA, et al.  The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014;15:382–392. doi: 10.1016/j.chom.2014.02.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2014.02.005</ArticleId>
            <ArticleId IdType="pmc">PMC4059512</ArticleId>
            <ArticleId IdType="pubmed">24629344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rühlemann MC, Solovjeva MEL, Zenouzi R, et al.  Gut mycobiome of primary sclerosing cholangitis patients is characterised by an increase of Trichocladium griseum and Candida species. Gut. 2020;69:1890–1892. doi: 10.1136/gutjnl-2019-320008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2019-320008</ArticleId>
            <ArticleId IdType="pmc">PMC7497579</ArticleId>
            <ArticleId IdType="pubmed">31653787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kulaksiz H, Rudolph G, Kloeters-Plachky P, et al.  Biliary candida infections in primary sclerosing cholangitis. J Hepatol. 2006;45:711–716. doi: 10.1016/j.jhep.2006.07.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2006.07.022</ArticleId>
            <ArticleId IdType="pubmed">16979779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serra N, Di Carlo P, D’Arpa F, et al.  Human bile microbiota: a retrospective study focusing on age and gender. J Infect Public Health. 2021;14:206–213. doi: 10.1016/j.jiph.2020.11.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jiph.2020.11.005</ArticleId>
            <ArticleId IdType="pubmed">33486377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tyc O, Jansen C, Schierwagen R, et al.  Variation in bile microbiome by the etiology of cholestatic liver disease. Liver Transpl. 2020;26:1652–1657. doi: 10.1002/lt.25882.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/lt.25882</ArticleId>
            <ArticleId IdType="pmc">PMC8462439</ArticleId>
            <ArticleId IdType="pubmed">32885580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dangtakot R, Intuyod K, Ahooja A, et al.  Profiling of bile microbiome identifies district microbial population between choledocholithiasis and cholangiocarcinoma patients. Asian Pac J Cancer Prev. 2021;22:233–240. doi: 10.31557/APJCP.2021.22.1.233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.31557/APJCP.2021.22.1.233</ArticleId>
            <ArticleId IdType="pmc">PMC8184169</ArticleId>
            <ArticleId IdType="pubmed">33507704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pereira P, Aho V, Arola J, et al.  Bile microbiota in primary sclerosing cholangitis: impact on disease progression and development of biliary dysplasia. PLoS ONE. 2017;12:e0182924. doi: 10.1371/journal.pone.0182924.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0182924</ArticleId>
            <ArticleId IdType="pmc">PMC5552186</ArticleId>
            <ArticleId IdType="pubmed">28796833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liwinski T, Zenouzi R, John C, et al.  Alterations of the bile microbiome in primary sclerosing cholangitis. Gut. 2020;69:665–672. doi: 10.1136/gutjnl-2019-318416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2019-318416</ArticleId>
            <ArticleId IdType="pubmed">31243055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minich JJ, Zhu Q, Janssen S, et al KatharoSeq enables high-throughput microbiome analysis from low-biomass samples. mSystems 3:. 10.1128/mSystems.00218-17</Citation>
        </Reference>
        <Reference>
          <Citation>Vieira SM, Hiltensperger M, Kumar V, et al Translocation of a gut pathobiont drives autoimmunity in mice and humans</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang H, Liu M, Liu X, et al.  Bifidobacterium animalis ssp Lactis 420 mitigates autoimmune hepatitis through regulating intestinal barrier and liver immune cells. Front Immunol. 2020;11:569104. doi: 10.3389/fimmu.2020.569104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.569104</ArticleId>
            <ArticleId IdType="pmc">PMC7573389</ArticleId>
            <ArticleId IdType="pubmed">33123141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, Liu M, Zhong W, et al.  Leaky gut driven by dysbiosis augments activation and accumulation of liver macrophages via RIP3 signaling pathway in autoimmune hepatitis. Front Immunol. 2021;12:624360. doi: 10.3389/fimmu.2021.624360.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2021.624360</ArticleId>
            <ArticleId IdType="pmc">PMC8027109</ArticleId>
            <ArticleId IdType="pubmed">33841405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xue R, Zhang H, Pan J, et al.  Peripheral dopamine controlled by gut microbes inhibits invariant natural killer T cell-mediated hepatitis. Front Immunol. 2018;9:2398. doi: 10.3389/fimmu.2018.02398.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.02398</ArticleId>
            <ArticleId IdType="pmc">PMC6199378</ArticleId>
            <ArticleId IdType="pubmed">30386344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheng L, Jena PK, Hu Y, et al.  Hepatic inflammation caused by dysregulated bile acid synthesis is reversible by butyrate supplementation. J Pathol. 2017;243:431–441. doi: 10.1002/path.4983.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/path.4983</ArticleId>
            <ArticleId IdType="pmc">PMC5953422</ArticleId>
            <ArticleId IdType="pubmed">28892150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang JJ, Yang G-X, Zhang WC, et al.  Escherichia coli infection induces autoimmune cholangitis and anti-mitochondrial antibodies in non-obese diabetic (NOD).B6 (Idd10/Idd18) mice. Clin Exp Immunol. 2014;175:192–201. doi: 10.1111/cei.12224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cei.12224</ArticleId>
            <ArticleId IdType="pmc">PMC3892410</ArticleId>
            <ArticleId IdType="pubmed">24128311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mattner J, Savage PB, Leung P, et al.  Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe. 2008;3:304–315. doi: 10.1016/j.chom.2008.03.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2008.03.009</ArticleId>
            <ArticleId IdType="pmc">PMC2453520</ArticleId>
            <ArticleId IdType="pubmed">18474357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haruta I, Kikuchi K, Nakamura M, et al.  Involvement of commensal bacteria may lead to dysregulated inflammatory and autoimmune responses in a mouse model for chronic nonsuppurative destructive cholangitis. J Clin Immunol. 2012;32:1026–1037. doi: 10.1007/s10875-012-9712-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10875-012-9712-1</ArticleId>
            <ArticleId IdType="pubmed">22661269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma H-D, Zhao Z-B, Ma W-T, et al.  Gut microbiota translocation promotes autoimmune cholangitis. J Autoimmun. 2018;95:47–57. doi: 10.1016/j.jaut.2018.09.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2018.09.010</ArticleId>
            <ArticleId IdType="pmc">PMC6290354</ArticleId>
            <ArticleId IdType="pubmed">30340822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Isaacs-Ten A, Echeandia M, Moreno-Gonzalez M, et al.  Intestinal microbiome-macrophage crosstalk contributes to cholestatic liver disease by promoting intestinal permeability in mice. Hepatology. 2020;72:2090–2108. doi: 10.1002/hep.31228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.31228</ArticleId>
            <ArticleId IdType="pmc">PMC7839474</ArticleId>
            <ArticleId IdType="pubmed">32168395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tabibian JH, O’Hara SP, Trussoni CE, et al.  Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology. 2016;63:185–196. doi: 10.1002/hep.27927.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.27927</ArticleId>
            <ArticleId IdType="pmc">PMC4670294</ArticleId>
            <ArticleId IdType="pubmed">26044703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tedesco D, Thapa M, Chin CY, et al.  Alterations in intestinal microbiota lead to production of interleukin 17 by intrahepatic γδ T-cell receptor-positive cells and pathogenesis of cholestatic liver disease. Gastroenterology. 2018;154:2178–2193. doi: 10.1053/j.gastro.2018.02.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2018.02.019</ArticleId>
            <ArticleId IdType="pmc">PMC5985208</ArticleId>
            <ArticleId IdType="pubmed">29454797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao L, Schneider KM, Galvez EJC, et al.  Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis. Gut. 2019;68:1477–1492. doi: 10.1136/gutjnl-2018-316670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2018-316670</ArticleId>
            <ArticleId IdType="pubmed">30872395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fuchs CD, Paumgartner G, Mlitz V, et al.  Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2-/- mice by modulating composition, signalling and excretion of faecal bile acids. Gut. 2018;67:1683–1691. doi: 10.1136/gutjnl-2017-314553.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2017-314553</ArticleId>
            <ArticleId IdType="pmc">PMC6109278</ArticleId>
            <ArticleId IdType="pubmed">29636383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamoto N, Sasaki N, Aoki R, et al.  Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol. 2019;4:492–503. doi: 10.1038/s41564-018-0333-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41564-018-0333-1</ArticleId>
            <ArticleId IdType="pubmed">30643240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu S-P, Bian Z-H, Zhao Z-B, et al.  Animal models of autoimmune liver diseases: a comprehensive review. Clin Rev Allergy Immunol. 2020;58:252–271. doi: 10.1007/s12016-020-08778-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12016-020-08778-6</ArticleId>
            <ArticleId IdType="pubmed">32076943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosshart SP, Herz J, Vassallo BG, et al (2019) Laboratory mice born to wild mice have natural microbiota and model human immune responses. Science (80- ) 365:. 10.1126/science.aaw4361</Citation>
        </Reference>
        <Reference>
          <Citation>Hui W, Li T, Liu W, et al.  Fecal microbiota transplantation for treatment of recurrent C difficile infection: an updated randomized controlled trial meta-analysis. PLoS One. 2019;14:e0210016. doi: 10.1371/journal.pone.0210016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0210016</ArticleId>
            <ArticleId IdType="pmc">PMC6343888</ArticleId>
            <ArticleId IdType="pubmed">30673716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ott SJ, Waetzig GH, Rehman A, et al.  Efficacy of sterile fecal filtrate transfer for treating patients with Clostridium difficile infection. Gastroenterology. 2017;152:799–811.e7. doi: 10.1053/j.gastro.2016.11.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2016.11.010</ArticleId>
            <ArticleId IdType="pubmed">27866880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeFilipp Z, Bloom PP, Torres Soto M, et al.  Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med. 2019;381:2043–2050. doi: 10.1056/NEJMoa1910437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1910437</ArticleId>
            <ArticleId IdType="pubmed">31665575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suez J, Zmora N, Segal E, Elinav E. The pros, cons, and many unknowns of probiotics. Nat Med. 2019;25:716–729. doi: 10.1038/s41591-019-0439-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-019-0439-x</ArticleId>
            <ArticleId IdType="pubmed">31061539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferreira-Halder CV, Sousa Faria AV, de Andrade SS. Action and function of Faecalibacterium prausnitzii in health and disease. Best Pract Res Clin Gastroenterol. 2017;31:643–648. doi: 10.1016/j.bpg.2017.09.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bpg.2017.09.011</ArticleId>
            <ArticleId IdType="pubmed">29566907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wegh CAM, Geerlings SY, Knol J, et al.  Postbiotics and their potential applications in early life nutrition and beyond. Int J Mol Sci. 2019;20:4673. doi: 10.3390/ijms20194673.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20194673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen H, Nwe P-K, Yang Y, et al.  A forward chemical genetic screen reveals gut microbiota metabolites that modulate host physiology. Cell. 2019;177:1217–1231.e18. doi: 10.1016/j.cell.2019.03.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2019.03.036</ArticleId>
            <ArticleId IdType="pmc">PMC6536006</ArticleId>
            <ArticleId IdType="pubmed">31006530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kortright KE, Chan BK, Koff JL, Turner PE. Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe. 2019;25:219–232. doi: 10.1016/j.chom.2019.01.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2019.01.014</ArticleId>
            <ArticleId IdType="pubmed">30763536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Htet TD, Godneva A, Liu Z, et al.  Rationale and design of a randomised controlled trial testing the effect of personalised diet in individuals with pre-diabetes or type 2 diabetes mellitus treated with metformin. BMJ Open. 2020;10:e037859. doi: 10.1136/bmjopen-2020-037859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjopen-2020-037859</ArticleId>
            <ArticleId IdType="pmc">PMC7552859</ArticleId>
            <ArticleId IdType="pubmed">33040003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beghini F, McIver LJ, Blanco-Míguez A, et al.  Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. Elife. 2021;10:e65088. doi: 10.7554/eLife.65088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.65088</ArticleId>
            <ArticleId IdType="pmc">PMC8096432</ArticleId>
            <ArticleId IdType="pubmed">33944776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCoubrey LE, Elbadawi M, Orlu M, et al.  Harnessing machine learning for development of microbiome therapeutics. Gut Microbes. 2021;13:1–20. doi: 10.1080/19490976.2021.1872323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/19490976.2021.1872323</ArticleId>
            <ArticleId IdType="pmc">PMC7872042</ArticleId>
            <ArticleId IdType="pubmed">33522391</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
